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Abstract
Selective IgA deficiency (IgAD; serum IgA,0.07 g/l) is the most common form of human primary immune deficiency,
affecting approximately 1:600 individuals in populations of Northern European ancestry. The polygenic nature of IgAD is
underscored by the recent identification of several new risk genes in a genome-wide association study. Among the
characterized susceptibility loci, the association with specific HLA haplotypes represents the major genetic risk factor for
IgAD. Despite the robust association, the nature and location of the causal variants in the HLA region remains unknown. To
better characterize the association signal in this region, we performed a high-density SNP mapping of the HLA locus and
imputed the genotypes of common HLA-B, -DRB1, and -DQB1 alleles in a combined sample of 772 IgAD patients and 1,976
matched controls from 3 independent European populations. We confirmed the complex nature of the association with the
HLA locus, which is the result of multiple effects spanning the entire HLA region. The primary association signal mapped to
the HLA-DQB1*02 allele in the HLA Class II region (combined P=7.69610
257; OR=2.80) resulting from the combined
independent effects of the HLA-B*0801-DRB1*0301-DQB1*02 and -DRB1*0701-DQB1*02 haplotypes, while additional
secondary signals were associated with the DRB1*0102 (combined P=5.86610
217; OR=4.28) and the DRB1*1501
(combined P=2.24610
235; OR=0.13) alleles. Despite the strong population-specific frequencies of HLA alleles, we found a
remarkable conservation of these effects regardless of the ethnic background, which supports the use of large multi-ethnic
populations to characterize shared genetic association signals in the HLA region. We also provide evidence for the location
of association signals within the specific extended haplotypes, which will guide future sequencing studies aimed at
characterizing the precise functional variants contributing to disease pathogenesis.
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Introduction
The major histocompatibility complex (MHC) locus has been
one of the most intensively studied regions in the vertebrate
genome since it was first discovered in the mouse in 1936 [1]. In
humans, gene products from the MHC were initially identified as
surface markers on leucocytes, which led to its alternative
designation as the human leukocyte antigen (HLA) complex. This
genomic region spans approximately 3.6 megabase pairs (Mb) of
genomic sequence and encodes over 200 genes, many of which
with a defined immune function [2]. More recently, the definition
of an extended MHC region (xMHC) has been proposed, which
encompasses approximately 7.6 Mb and 421 annotated gene loci
[3]. The HLA locus contains the canonical HLA Class I and Class
II gene clusters. Class I HLA molecules are expressed on the
surface of most human cells, while constitutive expression of Class
II molecules is restricted to antigen presenting cells, including
dendritic cells, macrophages and B cells. These molecules function
PLoS Genetics | www.plosgenetics.org 1 January 2012 | Volume 8 | Issue 1 | e1002476to present peptide antigens to T cells to initiate adaptive immune
responses.
The relevance of this locus to the pathogenesis of common
human diseases is clearly evidenced by the reported association of
polymorphisms in the HLA region with over one hundred
diseases, particularly autoimmune and inflammatory conditions
[4]. Similarly, the genetic association with HLA markers has been
well documented in selective IgA deficiency (IgAD; serum IgA
concentration ,0.07 g/l), the most common form of human
primary immunodeficiency [5,6]. However, despite the robust
association with a large number of immune-mediated conditions,
the conservation of some ancestral haplotypes [7,8], which can
encompass large genomic segments containing many genes, has
greatly impaired our ability to unambiguously identify the gene(s)
contributing to disease susceptibility.
The HLA was first described as a risk locus for IgAD through
the association with HLA Class I and Class II markers [9–11] and
ascribed to specific conserved haplotypes. Most notably, the
extended HLA-A*01-B*08-DRB1*0301-DQB1*02 (DR3) haplo-
type has been identified as the single strongest genetic risk factor
for IgAD in Northern European populations [12]. A striking 13%
of DR3 homozygotes have been estimated to be IgA deficient [13],
although this figure might be inflated due to publication bias [14].
An even larger proportion (67%) appears to suffer from at least
one form of Ig deficiency, including selective IgG3, IgG4, IgD and
IgA deficiency [15]. Conversely, the HLA-DRB1*1501-DQB1*06
(DR2) haplotype, has been shown to confer strong protection
against IgAD, with homozygous individuals showing a virtual
complete protection from the disease [12]. Positive associations
have also been described with 2 other extended haplotypes,
namely the HLA-B*14-DRB1*0102-DQB1*05 (DR1) and the
HLA-B*44-DRB1*0701-DQB1*02 (DR7) haplotypes [12]. Inter-
estingly, the risk conferred by DR7 and particularly DR1
haplotypes has been shown to be greater than that conferred by
DR3 haplotypes in populations of Southern European ancestry
[16–18]. Despite the strong association at the HLA locus, there
has been no consensus as to the precise location of the causal
variants within these haplotypes, with some groups suggesting its
placement to the telomeric end of the HLA Class III region [19–
21] and others in the HLA Class II region [22,23].
To refine the complex association signals in the extended MHC,
we genotyped a panel of 1,686 SNPs and imputed with high
confidence the genotype of 9,905 SNPs spanning the entire HLA
locus. We used the genotype information to reconstruct the
individual long-range haplotypes and impute common HLA
alleles. Here, we report single and multi-marker association
analyses of both HLA and non-HLA variants with IgAD in a
combined sample of 772 IgAD cases and 1976 matched controls
from 3 independent European populations. These data provide
the most complete fine-mapping effort of the HLA locus in IgAD
to date.
Results
Association of HLA and non-HLA common variants using
a high-density SNP–based mapping approach
We recently performed a genome-wide association study of
IgAD and reported the disease-association of 2 novel non-HLA
loci: IFIH1 and CLEC16A [24]. We also confirmed the HLA locus
as the strongest genetic risk factor for IgAD [24]. To better
characterize the association at the HLA locus, we used the
genotyping data from 1,686 SNPs located within a 10 Mb region
of chromosome 6 (25–35 Mb) containing the extended HLA
region, and employed a long-range haplotype phasing approach to
infer, with high confidence, individual HLA haplotypes. To
further refine the fine mapping of this region, we also imputed the
genotypes of an additional 9,905 SNPs using the HapMap2
reference set.
Allele-based association tests were then performed on the 1,686
genotyped and 9,905 imputed SNPs and on the imputed HLA
alleles that survived stringent quality control steps in 430 IgAD
cases and 1090 controls from Sweden and Iceland and in two
independent replication cohorts from Spain (256 cases and 322
controls) and Finland (86 cases and 564 controls). To avoid
spurious associations due to specific population differences that
are associated with the HLA locus, we used all available genome-
wide genotyping data to describe the population substructure
using a principal component method [25,26]. Exclusion of the
genetic outliers in each population ensured the genetic homoge-
neity of our sample, as evidenced by the modest distributional
inflation (lGC) observed in each case-control series (Sweden/
Iceland: lGC=1.05; Spain: lGC=1.05; Finland: lGC=1.04).
Allele-based association tests were performed in each population
independently, and combined P values were calculated using a
meta-analysis. In addition, we also phased the genotypes from a
set of 49 selected SNPs spanning the classical MHC region to
reconstruct the extended haplotypes in each individual. SNP
selection was optimized to combine a set of 11 SNPs that best
captured the information of the known HLA alleles that were
typed directly in our sample, together with a second set of 38
common SNPs, which had low pairwise LD and were distributed
uniformly across the classical HLA region. Importantly, this
strategy ensured that we recapitulated the full diversity of the
haplotype structure of the HLA locus, and allowed us to map the
individual recombination events within the extended haplotypes
(see Methods). We tested the association of the more common
extended haplotypes and used the haplotype background
information to map the recombination events more accurately
and the location of the putative causal variants within each
specific disease-associated haplotype.
Author Summary
The human leukocyte antigen (HLA) locus is robustly
associated with many immune-mediated conditions. How-
ever, identification of the genetic variants contributing to
the disease pathophysiology has been greatly hampered
by the extensive chromosomal conservation within this
genomic region. To better understand the association of
the HLA locus in selective IgA deficiency (IgAD), we used
an extensive genotyping database from a recent genome-
wide association study (GWAS) to generate a high-density
SNP map of this region in a combined sample of .2,700
individuals from 3 independent European populations. In
addition, we took advantage of recent methodological
advances to impute the more common HLA-B, -DRB1, and -
DQB1 alleles in all subjects. We confirmed the strong
disease-association of the HLA locus and identified several
different signals located in specific conserved HLA
haplotypes contributing independent risk or protection
for IgAD. Further analysis of the chromosomal sequences
associated with the associated HLA alleles allowed us to
refine the mapping of the susceptibility variants. These
findings represent the most comprehensive high-density
SNP mapping of the HLA locus in IgAD to date and provide
important new information as to the location of the
genetic variants contributing to this common immune
deficiency.
Fine-Mapping of the HLA Locus in IgA Deficiency
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HLA-B*0801-DRB1*0301 and HLA-DRB1*0701-DQB1*02
haplotypes is responsible for the primary association
signal in the HLA Class II region
The primary association peak in the HLA locus mapped to the
Class II region (Figure 1). Consistent with a recent report, that
included approximately 270 overlapping IgAD patients and 670
controls from the Swedish cohort used in this study [27], the
strongest association was observed with the imputed HLA-
DQB1*02 allele (combined P=7.69 610
257; OR=2.80, 95% CI
2.46–3.20; Figure 1). The association with the DQB1*02 allele
was approximately 6 orders of magnitude more significant than
the most associated imputed SNP, which mapped to the HLA-
DRB1 gene (rs3891175; combined P=4.31 610
251; OR=2.82,
95% CI 2.44-2.27) and over 10
10-fold more significant than the
most associated genotyped marker (rs204999; combined P=
2.02610
246; OR=2.47, 95% CI 2.18–2.81; Figure 1).
HLA-DQB1*02 is a common allele in populations of European
ancestry, and is linked to both the HLA-DRB1*0301 and -
DRB1*0701 alleles that have been previously described as strong
IgAD risk factors. In this study, we confirmed the disease risk
conferred by the DRB1*0301 (combined P=1.56610
234;
OR=2.49, 95% CI 2.14–2.90; Table 1) and DRB1*0701 alleles
(combined P=8.68610
217; OR=2.03, 95% CI 1.70–2.41;
Table 1). One important distinction between these 2 haplotypes
is that the DRB1*0301 allele is typically linked with the
DQB1*0201 allele, while the DRB1*0701 allele is linked to the
DQB1*0202 variant [28]. These two DQB1*02 alleles differ only
by one amino acid in the third exon, and are therefore difficult to
differentiate by traditional typing methods using 2-digit resolution.
Despite the sequence similarity, the HLA Class II sequences
surrounding these 2 alleles are distinct and contain different HLA-
DQA1 alleles. To discriminate between the two HLA-DQB1*02
alleles, we genotyped the HLA-DQB1 gene in 15 Finnish IgAD
patients carrying the DQB1*02 allele (5 DRB1*0301/X, 5
DRB1*0701/X and 5 DRB1*0301/DRB1*0701 heterozygous
individuals) using 4-digit resolution. We confirmed that all
DRB1*0301 alleles were always associated with the DQB1*0201
allele, while 9/10 (90%) of the DRB1*0701 alleles were associated
with the DQB1*0202 subtype (data not shown).
Analysis of the haplotype structure showed that, as noted
previously [29], DRB1*0301 haplotypes showed very low levels of
historical recombination and were generally found as extended
conserved haplotypes (Figure 2). In our sample, of the 907
haplotypes carrying the DRB1*0301 allele, 634 (69.9%) encom-
Figure 1. Primary association signal of the HLA locus with IgAD. Allele-based association tests were performed for all 1,686 genotyped SNPs
and imputed HLA alleles (represented by yellow diamonds) and for the 9,905 SNPs imputed with high confidence using the HapMap2 reference set
(represented by light blue circles). All association results are represented as the 2log10 of the combined P values (left y-axis). The most associated SNP
and HLA allele are indicated by yellow squares. Recombination rates from the HapMap CEU are depicted in dark blue (right y-axis). Genomic positions
on the x-axis are based on the NCBI Build 36 (hg 18) assembly. CI, confidence interval; Mb, megabase pairs.
doi:10.1371/journal.pgen.1002476.g001
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PLoS Genetics | www.plosgenetics.org 4 January 2012 | Volume 8 | Issue 1 | e1002476passed the extended HLA-B*0801-DRB1*0301-DQB1*02 haplo-
type, and 273 (30.1%) were recombinant (non-B*0801) haplotypes.
Importantly, recombinant DRB1*0301 haplotypes that lacked
B*0801 showed no evidence of association with IgAD (combined
P=0.42; OR=1.10, 95% CI 0.84–1.44; Table 1). In contrast, the
extended HLA-B*0801-DRB1*0301-DQB1*02 haplotype was
found to be the most disease-associated HLA haplotype (combined
P=3.37610
243; OR=3.33, 95% CI 2.79–3.97; Table 1).
The distribution of DRB1*03 haplotypes varied across the
populations studied, with a higher percentage of extended HLA-
B*0801-DRB1*0301-DQB1*02 haplotypes in Northern Europe-
ans, as compared with the Spanish population (Table S1), likely
reflecting the increased frequency of HLA-B*18-DRB1*0301-
DQB1*02 haplotypes in Southern Europeans. Nevertheless, in all
3 cohorts, we observed a consistent and significant increase in the
frequency of extended B*0801-DRB1*0301-DQB1*02 compared
Figure 2. Representation of the haplotypes carrying the HLA-DRB1 alleles most associated with IgAD. Reconstructed extended
haplotypes using the final set of 49 SNPs spanning the classical HLA region were aligned to the respective extended haplotype. Shown here are the
reconstructed haplotypes carrying the HLA-DRB1*03 (a), -DRB1*07 (b), -DRB1*0102 (c) and -DRB1*15 (d) alleles. Recombinant haplotypes represent all
haplotypes containing the same HLA-DRB1 allele in association with a different HLA-B allele, as compared to the respective extended haplotype.
Vertical bars delimit the HLA Class III region. N, Number of haplotypes. Haplotype frequencies in the Swedish/Icelandic, Spanish and Icelandic cohorts
are detailed in Table 1.
doi:10.1371/journal.pgen.1002476.g002
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PLoS Genetics | www.plosgenetics.org 5 January 2012 | Volume 8 | Issue 1 | e1002476to recombinant (non-B*0801) DRB1*0301 haplotypes in IgAD
cases (combined P=6.3610
29; OR=2.65, 95% CI 1.90–3.71;
Table S1). Similarly, recombinant (non-DRB1*0301) B*0801
haplotypes were also not associated with IgAD (combined
P=0.228; OR=0.92, 95% CI 0.64–1.33; data not shown). Given
the strong effect size of the risk allele present on the extended
HLA-B*0801-DRB1*0301-DQB1*02 haplotype, we have 100%
and 96% power to detect the association with the observed
recombinant (non-B*0801) DRB1*0301 and (non-DRB1*0301)
B*0801 haplotypes, respectively, at a significance level (a)o f
5610
25, and even 100% and 50% power at a much more
stringent genome-wide significant threshold of 5610
28 (Table S2).
We next performed a conditional logistic regression analysis,
using the genotype of the extended HLA-B*0801-DRB1*0301-
DQB1*02 as a covariate. The imputed HLA-DRB1*0701 allele
was found to be the most significantly associated marker
(combined Pcond=1.77610
222; Figure 3).
In contrast to DRB1*0301-containing haplotypes, haplotypes
linked to the DRB1*0701 allele have a high rate of historical
recombination (Figure 2). Although, DRB1*0701 is found
frequently within the HLA-B*13-DRB1*0701-DQB1*02, B*44-
DRB1*0701-DQB1*02 and B*57-DRB1*0701-DQB1*0303 ex-
tended haplotypes, the DRB1*0701 allele can also be found on
other haplotypes, in association with different HLA Class I and
Class II alleles (Figure 2). However, all DRB1*07 haplotypes
carrying the DQB1*02 allele were found to be similarly associated
with increased risk to IgAD (combined P=6.35610
217;O R=2 . 2 3 ,
95% CI 1.83–2.72; Table 1). Conversely, we found no strong
evidence for the association of recombinant (non-DQB1*02)
DRB1*07 haplotypes with IgAD (combined P=0.027; OR=1.34,
95%CI0.96–1.86; Table1).Further supportingthisobservation,we
have over 80% power to detect the association of recombinant (non-
DQB1*02) DRB1*07 haplotypes at a=5 610
28 (Table S2). These
data point to an important role of the DQB1*0202 allele, or a region
in tight linkage with DQB1*0202, in the association of the
DRB1*0701-DQB1*02 haplotypes with IgAD. In summary, the
data suggest that DRB1*0301 and DRB*0701 haplotypes indepen-
dently contribute to risk of IgAD, and the signal at DQB1*02 is
essentially the sum of these independent effects.
The HLA-B*1402-DRB1*0102-DQB1*05 haplotype is an
independent risk factor for IgAD
After further conditioning on both the HLA-B*0801-DRB1*03-
DQB1*02 and –DRB1*0701-DQB1*02 haplotypes, the most
significant residual HLA association signal corresponded to the
HLA-DRB1*0102 allele (Pcond=2.95610
219; Figure 3). Associa-
tion of the DRB1*01 allele with IgAD has been well documented,
Figure 3. Secondary association signals in the HLA locus. Combined P values are shown for all SNPs and imputed HLA alleles, following
conditioning on the HLA-B*0801-DRB1*0301-DQB1*02 (red diamonds), the HLA-B*0801-DRB1*0301-DQB1*02+HLA-DRB1*0701-DQB1*02 (yellow
triangles) and the HLA-B*0801-DRB1*0301-DQB1*02+HLA-DRB1*0701-DQB1*02+HLA-DRB1*0102 (green circles) haplotypes. All association results are
represented as the 2log10 of the combined P values (left y-axis). The most associated SNP and HLA allele in each step of the stepwise conditional
logistic regression analysis are indicated by squares. Recombination rates from the HapMap CEU are depicted in blue (right y-axis). Genomic positions
on the x-axis are based on the NCBI Build 36 (hg 18) assembly. Mb, megabase pairs.
doi:10.1371/journal.pgen.1002476.g003
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PLoS Genetics | www.plosgenetics.org 6 January 2012 | Volume 8 | Issue 1 | e1002476and contains both the more common DRB1*0101 and the less
common DRB1*0102 subtypes. Importantly, we found that the
association with IgAD was exclusively contributed by haplotypes
containing the DRB1*0102 allele, which showed association with
risk in all 3 independent European populations (combined
P=5.86610
217; OR=4.28, 95% CI 2.92–6.26; Table 1). Con-
versely, we found essentially no evidence for the association of the
HLA-DRB1*0101-DQB1*05 haplotype with IgAD (combined
P=0.038; OR=1.17, 95% CI 0.98–1.39; Table 1).
Haplotype analysis showed that the DRB1*0102 is usually
present on the extended B*1402-DRB1*0102-DQB1*0501 hap-
lotype, which is a rare haplotype in Northern Europeans (0.2%
allele frequency), but more common in the Spanish population
(3% allele frequency; Table 1). Nevertheless, the DRB1*0102
allele was a strong risk factor in all 3 cohorts, and contributed the
strongest individual effect of all the variants in the HLA region,
with a combined OR=4.59 (95% CI 2.89–7.30, Table 1). The
recombination rate was modest across the extended B*1402-
DRB1*0102-DQB1*05 haplotype. Of the 140 DRB1*0102-
containing haplotypes, 47 (33.6%) were recombinant (non-
B*1402; Figure 2). Despite the low number of recombinant
haplotypes, the trend towards increased risk was maintained, even
in the absence of the B*1402 allele (combined P=3.62610
23;
OR=3.22 95% CI 1.70–6.13; Table 1). In addition, in a single-
locus association test, the HLA-DRB1*0102 allele was found to be
more significantly associated with IgAD than the HLA-B*14 allele
alone (combined P=1.07610
212; OR=2.68; 95% CI 1.99–3.61;
data not shown), suggesting that the causal allele on the extended
B*1402-DRB1*0102-DQB1*05 is likely to be closer to the HLA-
DRB1 than to the HLA-B region.
The HLA DRB1*1501-DQB1*06 haplotype confers
protection from IgAD
To characterize additional independent loci, we next condi-
tioned on the HLA-B*0801-DRB1*03-DQB1*02, -DRB1*0701-
DQB1*02 and -DRB1*0102 alleles. The top residual association
signal corresponded to the protective HLA-DRB1*15 allele
(Pcond=3.26610
218; Figure 3). The protective effect of the
HLA-DRB1*15 allele was evident in all 3 cohorts (combined
P=2.24610
235; OR=0.13; 95% CI 0.09–0.19; Table 1), and was
observed for both DRB1*15 subtypes: the common DRB1*1501
allele, which was found to travel mostly on the extended B*0702-
DRB1*1501-DQB1*06 haplotype, and the rare DRB1*1502
allele.
DRB1*1501 haplotypes showed a relatively high rate of
historical recombination, and 51.2% excluded B*0702 (Figure 2).
However, the recombinant DRB1*15 haplotypes were equally
associated with protection from IgAD (combined P=3.70610
218;
OR=0.14, 95% CI 0.09–0.24; Table 1), suggesting that the causal
variant associated with the DRB1*1501 signal is located within the
linkage disequilibrium (LD) block containing HLA-DRB1 and
HLA-DQB1 in the Class II region.
Additional secondary association signals in the HLA
region
We next performed furtherconditionallogisticregression analysis,
conditioning on all four association signals noted above: B*0801-
DRB1*03-DQB1*02, -DRB1*0701-DQB1*02, DRB1*0102 and
DRB1*1501. The association signal was significantly reduced, with
only a few additional SNPs reaching the genome-wide association
significance threshold (P,5610
28; Figure S1). These SNPs mapped
specifically to two discretegenomic regions:(i) the BTNL2-HLA-DRA
locus on the telomeric end of the HLA class II region (rs743862;
Pcond=8.07610
214; Figure S1); and (ii) the HLA-DQB1 region
(rs9275141; Pcond=1.48 610
211; Figure S1), supporting the contri-
bution of these two additional regions to risk for IgAD.
Discussion
Markers in the HLA region represent the strongest genetic risk
factor associated with IgAD. Nevertheless, the extensive conser-
vation of the disease-associated haplotypes has hindered our ability
to confidently map the causal variants. In this study, we performed
the largest fine-mapping effort to date of the HLA locus in IgAD,
using a high-density SNP panel to characterize the complex
association at this locus, and to map the location of the
independent susceptibility loci.
The primary association signal in the HLA region was found to
be the HLA-DQB1*02 allele, including both the DQB1*0201 and
the DQB1*0202 alleles, which are linked with the HLA-DRB1*03
and -DRB1*07 haplotypes respectively. Using a haplotype-based
analysis, we found that the primary association signal was caused
by the additive effect of two independent susceptibility alleles
located on the extended HLA-B*08-DRB1*0301-DQB1*02 and
DRB1*0701-DQB1*02 haplotypes. Importantly, by using a long-
range haplotype phasing approach in a large sample size, we were
able to demonstrate that recombinant (non-B*0801) DRB1*0301
haplotypes carrying the DQB1*0201 allele showed no evidence of
association with disease. Despite the low historical recombination
rate on DRB1*0301 haplotypes, this approach allowed us to
compare a sufficiently large number of recombinant haplotypes to
increase our confidence in these observations. Interestingly, the
frequency of extended DRB1*0301 haplotypes was consistently
increased in IgAD patients from all 3 independent populations,
suggesting that, despite obvious population specific differences in
the distribution of these haplotypes, the underlying association
signal is identical in the different populations. Similarly, recombi-
nant (non-DRB1*0301) B*0801 haplotypes, showed no evidence of
association with IgAD, suggesting that the causal allele in the
extended HLA-B*08-DRB1*0301-DQB1*02 is likely to be located
in the telomeric end of the Class II region or in the Class III region.
To characterize further independent susceptibility loci, we next
performed a stepwise conditional logistic regression analysis.
Following conditioning on the primary HLA-B*08-DRB1*0301-
DQB1*02 association signal, the most significantly associated
HLA allele was found to be the DRB1*0701 allele, further
supporting the presence of an independent risk allele on DRB1*07
haplotypes. Despite the high recombination rate, we found that
DRB1*07 haplotypes carrying different Class I allele were all
similarly associated with IgAD. This was in contrast to non-
DQB1*0202 recombinant haplotypes, which showed no evidence
for association. The approach used in this study to compare the
association of the recombinant haplotypes in a large cohort to the
respective extended risk haplotypes was validated by power
calculations (summarized in Table S2) showing that the lack of
association of the recombinant (non-B*0801) DRB1*0301, (non-
DRB1*0301) B*0801 and (non-DQB1*02) DRB1*07 haplotypes
are not likely to be negative results due to a lack of power in the
study. Taken together, these data point to a causal role of the
DQB1*0202 allele or another variant in tight LD with it in the
HLA-DQA1–DQB1 locus in the Class II region.
We therefore propose a model whereby the strong association
observed with DQB1*02 allele results from the additive effect of
two independent risk loci: the DQB1*0202 allele, or another
marker in high LD and close proximity, traveling on HLA-
DRB1*0701-DQB1*0202 haplotypes and an independent allele,
most likely located within the border of the HLA Class III and
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B*0801-DRB1*0301-DQB1*02 haplotype.
Conditioning on the HLA-B*0801-DRB1*0301-DQB1*02 and
-DRB1*0701-DQB1*02 association signals, we characterized two
additional secondary association signals in the HLA region. The
HLA-DRB1*0102 allele was found to be a robust independent risk
allele, while DRB1*1501 was strongly protective. The most
significant secondary association signal was the DRB1*0102 allele
traveling on the extended HLA-B*1402-DRB1*0102-DQB1*05
haplotype. The prevalence of the B*1402-DRB1*0102 haplotype
showed marked population differences, and was more frequent in
populations of Southern European ancestry, as evidenced by the
4.5% allele frequency in the Spanish controls, compared to only
0.3% and 0.4% in the Swedish and Finnish controls respectively.
To have a better estimate of the DRB1*0102 allele frequency in
Northern Europeans, we performed an extensive survey of the
Swedish volunteer bone marrow donor registry (the Tobias
registry). We identified 296 copies of the B*1402-DRB1*0102
haplotype in 23,610 healthy individuals that were surveyed,
corresponding to a 0.6% allele frequency in the Swedish
population. Despite the specific population differences, the
DRB1*0102 association was consistent in all 3 independent
cohorts and showed the highest OR of any HLA allele.
Interestingly, the prevalence of IgAD in the Iranian population
has been shown to be similar to that observed in European
populations [30]. However, in Iranians the strongest HLA
association with IgAD is linked to the B*14 and DRB1*01 alleles
[31]. Taken together, these data clearly support the presence of a
strong risk variant on the conserved HLA-B*1402-DRB1*0102-
DQB1*05 haplotype. In fact, the effect size observed with this
allele is consistent with the presence of a rare variant with strong
penetrance on the HLA-B*1402-DRB1*0102-DQB1*05 back-
ground. Importantly, the lack of association with the more
common DRB1*0101 subtype, which shares the association with
the DQB1*05 allele, and the strong association with recombinant
DRB1*0102 haplotypes, supports the location of the causal variant
telomeric to the Class II region, most likely within the HLA Class
III region. It is interesting to note that the 2 missense mutations
that we have recently characterized in MSH5, L85F and P786S,
located in the HLA Class III region, travel specifically on this
extended haplotype [32]. It should be noted, however, that this
hypothesis was not supported by a recent study by Pozo et al,
suggesting that recombinant (non-DRB1*0102) haplotypes carry-
ing the L85F variant did not show evidence of association with
IgAD [33]. Nevertheless, the conservation and low frequency of
recombinant HLA-B*1402-DRB1*0102-DQB1*05 haplotypes in
European populations, warrant further analyses and a larger
sample size to confirm whether these missense mutations are the
causal variants for IgAD in this haplotype.
Another independent association signal identified was the
protective effectconferredbythe DRB1*1501allele. The association
of DRB1*1501 with disease protection has been well documented,
and further supports the important role of variants in the HLA Class
II region to the complex association signal observed on the HLA
locus. In fact, although the recombination rate in the DRB1*1501
haplotypes was elevated, all haplotypes sharing the HLA Class II
fragment containing the DRB1*1501 allele conferred similar
protection from IgAD. These data support the location of a
protective allele mapping specifically to the LD block containing the
HLA-DRB1 and HLA-DQB1 genes, and are consistent with the
previoushypothesis thatthe protective effectisdue to thepresenceof
a negatively charged aspartic acid in position 57 of the HLA-DQb
chain in DRB1*1501 haplotypes. In contrast, in risk haplotypes, the
aspartic acid residue is replaced by a neutral alanine [12].
Of interest, the association with the HLA locus in IgAD shares
some striking similarities with the association in type 1 diabetes
(T1D), where the DRB1*0301 allele is a strong risk factor and the
DRB1*1501 allele confers protection against the disease [34,35].
Similarly we have recently characterized the association between
IgAD and two novel non-HLA loci, IFIH1 and CLEC16A [24],
which are also known to be associated with T1D [36], suggesting a
shared genetic predisposition to both diseases. Despite these
similarities, there are some notable disease-specific differences in
the association with the HLA between the two conditions: i) the
DRB1*04 allele, one of the strongest risk factor in T1D, is not
associated with IgAD; ii) unlike T1D, the DRB1*0301 association
with IgAD is restricted to the extended B*0801-DRB1*0301-
DQB1*02 haplotype; iii) the DRB1*0701 allele, which is
associated with increased risk of IgAD is protective in T1D, while
the DRB1*0102 allele shows no evidence for association with T1D
[34,35]. These data suggest that the association with the HLA
locus is the result of multiple independent effects, some of which
are shared between different diseases. The characterization of the
association signal in the HLA region in different diseases may,
therefore, contribute important insights into the location of shared
genetic effects, and may help in the identification of the causal
variants in this genomic region.
In addition to the association of the extended HLA haplotypes,
we found further evidence for association of a few additional
independent markers in the HLA locus. Most notable were the
associations with SNPs in the BTNL2-HLA-DRA locus on the
telomeric end of the Class II region and in the HLA-DQB1 region.
Taken together, these data confirm that IgAD susceptibility is the
result of multilocus effects that span the entire HLA region.
In summary, we have mapped the primary susceptibility locus
to the HLA Class II region and found evidence for the association
of additional independent loci in Class III and Class I regions.
Importantly, the fine-mapping strategy provided a better resolu-
tion of the individual haplotype background and their specific
contribution to disease susceptibility. A summary of the putative
causal alleles and their respective location on the specific
haplotype background is depicted in Figure 4. These data are
consistent with a previous report from de la Concha et al. that used
a similar haplotype-based analysis to determine the location of the
IgAD causal variants in the HLA locus in the Spanish population
[37]. Here, we build on these results and extend the findings to
other European populations using a high-density SNP mapping
approach to reconstruct the individual HLA haplotypes with high
confidence. Taken together, these studies indicate that although
the HLA locus shows strong population differences, the haplotype-
specific genetic association signals are similar in the different
cohorts, suggesting that conserved causal variants, present in
ancestral haplotypes confer similar genetic predisposition to
disease independently of the ethnic background. This information
will also help generate better models to test the putative interaction
of specific HLA variants with the non-HLA risk loci identified
through the genome-wide association effort. In addition, the
characterization of the role of each specific haplotype to disease
susceptibility may provide important information about the precise
location of the functional variant(s) within the haplotype. These
data can provide a rationale to prioritize the specific conserved
haplotype segments that should be targeted for future sequencing
efforts. With the advent of more cost-effective sequencing
technologies, the complete re-sequencing of large haplotype
segments in a large targeted sample will become feasible, and
may be the only definitive approach to identify the functional
HLA variants present on these extremely conserved extended
haplotypes.
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Subjects
A total of 861 IgAD patients were enrolled from 4 different
centers across Europe: 418 were recruited at the Karolinska
Institutet, Karolinska University Hospital Huddinge; 34 were
recruited at the Landspitali – University Hospital, Reykjavik; 280
were recruited at the Hospital Universitario La Paz in Madrid;
and 129 were recruited from the Finnish Red Cross Blood Service
in Helsinki. The diagnosis of IgAD was obtained according to
accepted guidelines, with serum IgA levels below the detection
threshold (IgA,0.07 g/l), as measured by nephelometry in
multiple independent blood samples [5,38]. 2,184 geographically
matched control samples were obtained from 3 independent
sources: 1,115 control samples from the Epidemiological Investi-
gation of Rheumatoid Arthritis (EIRA) Swedish inception cohort;
373 samples collected at Hospital Clı ´nico San Carlos in Madrid;
and 693 samples from the Nordic Centre of Excellence in Disease
Genetics consortium (NCoEDG; Finnish controls). All DNA
samples were collected after approval from the relevant research
ethics and committees.
Genotyping and control quality
IgAD patients and the Spanish controls were genotyped at the
Feinstein Institute, New York, and the Swedish controls were
genotyped at The Genome Institute of Singapore. All genotyping
was performed using the Illumina BeadChip technology, on either
the HumanHap 300 or Human 610-quad chips. Genotyping data
for the Finnish controls was obtained from the NCoEDG, and was
generated using the Illumina CNV370 platform.
To assure high quality data on the final analysis, we used
stringent quality control measures, as described previously [24].
The final number of individuals passing all the quality control
steps in the 3 independent case-controls series were as follows:
Sweden/Iceland: 430 cases and 1,090 controls; Spain: 256 cases
and 322 controls; and Finland: 86 cases and 564 controls. We
observed minimal inflation of the median x
2 statistic in the 3
populations (Sweden/Iceland: lGC=1.05; Spain: lGC=1.05;
Finland: lGC=1.04), thus ruling out potential population
stratification issues on the different case-control series. Fine-
mapping of the HLA region was performed by extracting the
1,686 SNPs spanning 10 Mb of chromosome 6 (25–35 Mb) that
passed all quality control steps.
SNP imputation
SNP imputation of the HapMap2 (release# 24) reference
dataset was performed using IMPUTE [39], with default settings.
Imputation was performed using only the SNPs that passed quality
control and were genotyped in all 3 case-control series. To ensure
that only SNPs imputed with high confidence were included in the
final analysis, we only tested the association of SNPs reaching an
imputation score (proper_info statistic) .0.8 in each case-control
series.
Figure 4. Summary of most significant independent association signals in the HLA locus. For each conserved haplotype background the
critical region where the putative causal variant is more likely to be located is highlighted. Genomic positions on the x-axis are based on the NCBI
Build 36 (hg 18) assembly. Mb, megabase pairs.
doi:10.1371/journal.pgen.1002476.g004
Fine-Mapping of the HLA Locus in IgA Deficiency
PLoS Genetics | www.plosgenetics.org 9 January 2012 | Volume 8 | Issue 1 | e1002476HLA typing
The IgAD patients from Sweden, Iceland and Finland were
genotyped at the HLA-B, -DRB1 and -DQB1 loci using PCR-SSP
[40] employing the HLA-B low resolution and the HLA-DQ, -DR
SSP Combi Tray kits from Olerup SSP AB, Saltsjo ¨baden, Sweden.
In the Spanish samples, HLA-B was typed using the Low
Resolution SSP Typing kit by Biosynthesis (Lewisville, TX). HLA-
DRB1 typing (and subtyping) and -DQB1 typing were conducted
by PCR amplification and hybridization with allele-specific
oligonucleotides [41].
Imputation of genotypes at the common HLA-B, -DRB1,
and -DQB1 genes
The SNP data was used to impute the common HLA-B,- DRB1
and -DQB1 alleles in all the samples studied. The use of SNP data
has been previously shown to be useful in inferring HLA alleles by
taking advantage of the strong LD structure in the region. de
Bakker et al showed that using genotype information from just 1 to
3 neighboring SNPs (tagging SNPs), they were able to accurately
infer the genotypes of the most common HLA alleles [42].
Nevertheless, the accuracy of this tagging SNP approach is
affected by the variability of most classical HLA alleles, and does
not provide complete information about the haplotype back-
ground surrounding the HLA alleles and about the occurrence of
internal recombination events within the haplotypes. More
recently, a different approach has been proposed, using multi-
maker SNP data across the entire HLA region to infer the
haplotype context surrounding the alleles, and to provide a more
accurate estimation of the specific HLA alleles [43].
The SNP selection strategy employed in this study for haplotype
phasing included the initial selection of 11 HLA-tagging SNPs that
were found to be the most informative for the imputation of the
more common HLA-B, -DRB1 and -DQB1 alleles, using the tagger
algorithm implemented in PLINK [44]. Then, we supplemented
the set of tagging SNPs with a second set of 38 SNPs distributed
uniformly across the classical HLA region. Importantly, to capture
the full diversity of the haplotype structure and to map the
individual recombination events, SNP selection was restricted to
common and independent (low pairwise r
2) SNPs. Given the lack
of accuracy of the tagging approach to infer most HLA-B alleles,
we included a higher density of SNPs for the HLA Class I region.
The genotype information from the final set of 49 SNPs (listed in
Table S3) was used to reconstruct the individual long-range
haplotypes, using PHASE v2.1 [45], with the standard pre-defined
parameters. Missing genotypes from the final set of 49 SNPs were
also imputed during the phasing step.
The imputation of the common HLA alleles was then
performed by aligning the phased haplotypes and by defining,
visually, the longest segment of consecutive SNPs surrounding the
tagging SNP that uniquely identifies each common HLA allele.
This strategy was possible because we had access to a large
number of samples that were HLA typed at the HLA-B, HLA-
DRB1 and HLA-DQB1 genes. In fact, 2 or 4-digit HLA-B typing
data was available for 410 IgAD patients, while HLA-DRB1 and –
DQB1 data was available from 534 and 638 IgAD patients
respectively (Table S4).
To test the performance of the method, the sensitivity,
specificity and positive predictive value (PPV) were calculated on
both the training set and on an additional validation set of 79
IgAD patients that were used to determine the allele-specific
haplotype segments. Estimation of the sensitivity, specificity and
PPV of the imputed alleles in the validation set was very high
(Table S5). The only notable exceptions were the B*0702 allele,
which was found to be rare in the validation cohort, and the
DQB1*03 allele (Table S5). Given the computing-intensive nature
of the haplotype phasing, the number of SNPs used for this step
was limited, and, most likely, insufficient to fully characterize rare
HLA alleles. However, it was sufficient to accurately depict the
haplotype background of the common HLA alleles that have
previously been associated with risk or protection for IgAD.
Statistical analyses
Allele-based association tests. Allele-based association tests
were performed on allSNPs and imputed HLA alleles. Association of
all variants to disease was calculated using a 1-degree of freedom x
2
test, comparing the minor allele frequency in cases and controls in
each population. Haplotype association tests were performed using
a similar strategy, by comparing the frequency of the selected
haplotypeagainstall otherhaplotypescombinedincasesandcontrols
from each cohort. For imputed SNPs, allele-based association tests
were performed using SNPTEST (https://mathgen.stats.ox.ac.uk/
genetics_software/snptest/snptest.html). The association statistics
were corrected taking into account the accuracy of the imputation
method for each SNP. All allele-based association tests were per-
formed assuming an additive risk model.
Combined P values, were calculated performing a meta-analysis
of the 3 independent case-control series, using a weighted z-score
method implemented in the METAL software package (http://
www.sph.umich.edu/csg/abecasis/metal/). In each cohort, P
values were converted to z-scores taking into account the direction
of the effect relative to an arbitrary allele. A weighted sum of z-
scores was calculated by dividing the individual z-scores by the
square root of the sample size of each cohort and then dividing the
sum by the square root of the total sample size. The reported
combined P values were obtained by converting the meta-analysis
z-scores into two-tailed P values.
To calculate combined odds ratios, we used the Cochran-
Mantel-Haenszel method implemented in PLINK [44]. All odds
ratios were calculated relative to the minor allele on the Swedish/
Icelandic population. The genomic inflation factor was estimated
in each cohort from the median x
2 statistic after excluding all
SNPs from the HLA region.
Conditional regression analyses. To characterize all
independent association signals from the known HLA alleles, a
stepwise forward conditional logistic regression analysis was
performed on the 3 independent cohorts, controlling for the
genotypes of the most associated HLA alleles or haplotypes. The
analysis represents a regression of disease status on each genotyped
test SNP and imputed HLA allele, including the genotype at the
most associated HLA allele (coded as 0,1 and 2 according to the
number of minor alleles) as covariates. In each step the genotype of
the top residual associated HLA allele was added as an additional
covariate to the model and the association was calculated in all
remaining test SNPs and imputed HLA alleles. The process was
then repeated iteratively, until no additional HLA allele reached
genome-wide association. All conditional analyses were performed
using PLINK [44]. Conditional analyses were performed in each
case-control series independently, and combined conditional P
values were calculated using a meta-analysis, as described above.
Power calculations. The power to detect the association of the
observedrecombinanthaplotypeswithIgADwascalculatedusingthe
CaTS power calculator for association studies (http://www.sph.
umich.edu/csg/abecasis/CaTS/), assuming a multiplicative disease
model, a disease incidence of 1:500 and a single-stage study design.
To determine the effect size of the extended risk haplotypes, we first
computed the genotype relative risk (GRR) corresponding to the
observed frequencies of the risk allele in IgAD patients and controls.
T h es a m eG R Rw a st h e na p p l i e dt ot h er e s p e c t i v er e c o m b i n a n t
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significance level (a) of 0.05, 0.01, 5610
25 and 5610
28.
Supporting Information
Figure S1 Residual association signal in the HLA locus following
conditioning on all major association signals. Combined P values
are shown for all SNPs and imputed HLA alleles, following
conditional logistic regression analysis, using the genotypes at the
HLA-B*0801-DRB1*0301-DQB1*02, -DRB1*0701-DQB1*02, -
DRB1*0102 and -DRB1*15 alleles as covariates. Association results
are represented as the 2log10 of the combined P values (left y-axis),
and the most associated SNP (rs743862) and imputed HLA allele
(B*1501) are marked by squares. Recombination rates from the
HapMap CEU are depicted in blue (right y-axis). Genomic
positions on the x-axis are based on the NCBI Build 36 (hg 18)
assembly. The horizontal red line represents the genome-wide
significance threshold of P=5 610
28. Mb, megabase pairs.
(TIF)
Table S1 Distribution of HLA-DRB1*0301 haplotypes in the 3
cases-control series. Shown are summary statistics for the
distribution of extended and recombinant (non-B*0801) HLA-
DRB1*0301 haplotypes in the 3 case-control series. P values were
calculated using a two-tailed Fisher’s exact probability test
comparing the frequency of recombinant DRB1*0301 haplotypes
in cases and controls. Odds ratios were calculated relative to the
frequency of extended HLA-B*0801-DRB1*0301-DQB1*02 hap-
lotypes. Combined P value and odds ratio were calculated using a
Cochran-Mantel-Haenszel test.
a Extended DR3 represent all
extended HLA-B*0801-DRB1*0301-DQB1*02 haplotypes;
b Re-
combinant DR3 represent all recombinant (non-B*0801)
DRB1*0301 haplotypes. N, number of haplotypes; OR, odds
ratio.
(XLS)
Table S2 Power to detect the association of recombinant
haplotypes with IgAD. Power to detect the association of the
observed recombinant haplotypes with IgAD in our combined
cohort of 772 patients and 1,976 controls. Power calculations were
performed assuming a multiplicative model and a disease
incidence of 1:500. The relative risk of each recombinant
haplotype was estimated to be identical to the relative risk
observed for the respective extended risk haplotype. GRR,
genotype relative risk.
(XLS)
Table S3 Final set of SNPs used for the reconstruction of the
extended haplotypes. List of SNPs in the HLA locus selected to
reconstruct the extended haplotypes. Chromosomal positions are
based on the NCBI Build 36 (hg 18) assembly.
(XLS)
Table S4 HLA typing information in IgAD patients. Shown is
the number of IgAD patients from each case-control series where
2-digit or 4-digit HLA typing information for the HLA-B, -DRB1
and -DQB1 alleles was available. N, Number of patients included
in the study after applying all quality control filters.
(XLS)
Table S5 Performance of the HLA imputation method on the
training and validation sets. Performance of the imputation
method for estimating the HLA-B,- DRB1 and -DQB1 alleles in
this study. Accuracy of the method was estimated by calculating
the sensitivity, specificity and positive predictive value (PPV) in the
training set (consisting of 410, 534 and 638 individuals with known
HLA-B,- DRB1 and -DQB1 typing information, respectively) and
an independent validation set (consisting of 79 individuals).
(XLS)
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